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ABSTRACT 
This paper studies the effects that pharmaceutical expenditure and other medical non-durables has on health out-
comes, such as mortality and life expectancy. Some recent research is focused on the study of public expenditure in 
health and the correlation with positive health indicators, and also on the relative eﬀectiveness of various medical 
health care inputs. As a specific case of this research, we center our interest on the pharmaceutical expenditure among 
various European countries in order to compare if expenditures are effective in health results, or on the contrary, 
countries with higher levels of pharmacy consumption do not have better health indicators. We carried out a regres-
sion analysis with panel data. The results imply that there is a positive effect between pharmaceutical expenditure and 
health outcomes. 
Keywords: Pharmaceutical Expenditure, Health Outcomes, Panel-Data. 
El gasto farmacéutico como determinante de los resultados en 
salud en países de la UE 
RESUMEN 
Este trabajo estudia los efectos que el gasto farmacéutico y otros artículos médicos de uso frecuente tienen sobre los 
resultados en salud, en concreto sobre la mortalidad y la esperanza de vida. Algunos trabajos recientes se han cen-
trado en el estudio del gasto público en salud y su correlación con indicadores positivos de salud, así como la efecti-
vidad relativa de varios inputs en salud. Como caso concreto de esta línea de investigación, este trabajo se centra en el 
gasto farmacéutico en ciertos países de la Unión Europea, con el fin de comparar si dicho gasto es efectivo en los 
resultados en salud. La aproximación metodológica se basa en el análisis de datos de panel. Los resultados corrobo-
ran un efecto positivo entre el gasto y los resultados en salud. 
Palabras claves: Gasto farmacéutico, resultados en salud, datos de panel. 
JEL Classification: I1, I18 
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1. INTRODUCTION 
A considerable number of health economics research has been devoted to 
explaining the assignment of public expenditures and the returns they have on 
population, improving the life of the population in some way. Nowadays, there 
is an important economic crisis, which makes that line of research more neces-
sary. Although the crisis is affecting European Countries in different ways, 
almost all of them are suffering financial problems. There are a lot of solutions 
for reducing debt, but one of the most used is the cut in public spending in ser-
vices such as health, education or dependence. According to all of this, the 
knowledge about how expenditure on health affects population and the correla-
tion with good effects in life quality is a really important issue. On the other 
hand, nowadays the economic situation is not as good as we would like it to be, 
so it is necessary to valuate public resources in order to use them in the most 
effective way. To sort out and establish effects of policy interventions, it is 
necessary to apply models that can give us results in terms of effectiveness or in 
good population indicators.  
More specifically, the study of pharmaceutical expenditures and their 
association with health outcomes has a great interest when looking for effi-
ciency and the evaluation of the best way to assign resources in order to obtain 
the best results. 
Pharmaceutical expenditure has been increasing quickly during the last 
decades in almost all the developed countries due to the changes in the demo-
graphic structure. The OECD (2011) published a report to show the evolution of 
pharmaceutical spending across countries. They observed that between 2000 
and 2009, real pharmaceutical expenditure had grown by around 3.5% per year 
on average, more or less in the same magnitude as total health spending, which 
had increased by 4.0%. On the other hand, there were several differences bet-
ween countries; some countries such as Luxembourg, Norway and Italy had 
negative growth in pharmaceutical spending over this period, while in Ireland 
and Greece pharmaceutical spending was growing really fast and governments 
had taken emergency measures in order to reduce public expenditure. In other 
countries, such as France, Germany or the United Kingdom, price reductions on 
pharmaceuticals have been used as adjustment variables to contain health 
spending growth. 
We show that expenditures on pharmacy and other medical non-durables 
have a positive effect on life-expectancy at birth while its influence is negative 
for infant mortality, and in all cases the magnitude for the variables are higher 
for men than for women. 
The structure of this paper is as follows: in Section 2, a revision of the 
literature is presented; in Section 3, the data and methodology are described and 
finally the results and conclusions are shown in Sections 4 and 5, respectively.  
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2. LITERATURE REVIEW 
As we said before, while there are a significant number of studies that are 
focused on the research of productivity of health care resources on health status, 
only a few of them have disaggregated pharmaceutical expenditures from total 
health expenditures. 
If we focus on the first international studies analyzing these aspects; Wolfe 
(1986) and Wolfe and Gabay (1987) tried to find a positive marginal effect in 
the association between change in medical expenditures and change in health 
status. They used 22 countries which have data in 1996, 1997 and 1998 and 
estimated simultaneous equations to find a positive link between change in 
medical expenditures and changes in health outcomes. Besides, Anand and 
Revallion (1993) worked in a cross-sectional study of 22 countries in the mid-
1980s. They concluded that the capability of producing health was not related 
directly to economic growth. Furthermore, Babazono and Hillman (1994) ana-
lyzed the relationship between health outcomes and total health care spending. 
They concluded that health outcomes and health care spending are not corre-
lated. Also, the results indicated that the way the resources are allocated is more 
important than how much money is spent. Some years later, Zeynep Or (2000) 
studied the determinant associated with health outcomes for 21 OECD countries 
over the period 1970-1992. He studied GDP, public health expenditure, NOx 
emissions per capita, the consumption of alcohol and tobacco and also the diet 
as explaining variables. The study concluded that all the style life variables are 
related with the years of life lost and health expenditure was difficult to separate 
from GDP because of the high correlation that exists between them. 
Crémieux et al., (2001) studied the relationship between one particular 
health outcome (infant mortality at the state level in the U.S.) and pharma-
ceutical spending. They showed that pharmaceutical spending is an important 
determinant of infant mortality, as well as disposable income, the percentage of 
the population below the poverty line, the number of practicing physicians, the 
number of hospital beds, teenage birth rate, low-weight births, high school 
graduation rate and racial composition of state population are. Additionally, 
Crémieux et al., (2005) analyzed more homogenous data and they included a 
more complete set of controls for confounding factors than previous studies. 
Their results showed a strong statistical relationship between drug spending and 
health outcomes, especially for infant mortality and life-expectancy at 65. This 
relationship is almost always stronger for private drug spending than for public 
drug spending. The analysis further indicates that substantially better health 
outcomes are observed in provinces where higher drug spending occurs. 
Gowrisankaran and Town (2004) analyzed county-level mortality rates over 
time and they found that greater enrollment in Medicare care insurance plans 
without any drug subsidies was associated with higher mortality, but they did 
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not find any association between mortality and Medicare managed care plans 
with drug coverage. Moreover, Day and Tousignan (2005) estimated a dynamic 
model of the relationship between three variables: real per capita GDP, real per 
capita spending on health and an indicator of health outcomes. They found evi-
dence of a weak statistically-significant relationship between per capita health 
spending, health outcomes, and per capita GDP. The absence of a strong statis-
tical relationship may be due to model misspecification or may reflect the fact 
that at where the population has high levels of health, the returns to increases in 
health spending are small. A year later, Nixon and Ulmann (2006) estimated the 
relationship between healthcare expenditure and health outcomes for the coun-
tries in the European Union over the period from 1980 to 1995. They used life 
expectancy and infant mortality as measures of health outcomes. They con-
cluded that increases in health care expenditure are significantly associated with 
large improvements in infant mortality but only marginally in relation to life 
expectancy. 
Liu et al., in 2008 tried to assess the independent association between phar-
maceutical expenditures and health outcomes in 14 industrialized countries. 
They used data from the Organization for Economic Co-operation and Develop-
ment (OECD) to construct panel data set from 1985 to 2001. They estimated the 
relationship between pharmaceutical expenditures and potential years of life lost 
and life expectancy at ages 65 and 80 years for both males and females, using 
non-linear fixed-effects regression models that corrected for serial correlation. 
Pharmaceutical expenditures proved to be a robust correlate of health outcomes 
from 1985 to 2001 in this sample, when controlling for the effects of other 
variables likely to impact population health outcomes. Their estimates imply 
that a 10% increase in pharmaceutical expenditures during these years was 
associated with a 0.3% increase in female life expectancy at the age of 65, while 
a similar increase was associated with a 0.4% increase in male life expectancy 
at the age of 65 and a 0.5% increase at the age of 80. 
Martin et al., (2008) developed a theoretical model which allowed them to 
study the relationship between health care spending and health outcomes using 
instrumental variables methods. They used programme budgeting data prepared 
by 295 English Primary Care Trusts to model the link for two specific pro-
grammes of care: cancer and circulatory diseases. They showed that health care 
expenditure has a strong positive effect on outcomes in the two programmes of 
care investigated. More recently, Caliskan (2009) examined the effect of public 
and private pharmaceutical expenditures on life expectancy for 21 OECD coun-
tries. He used panel data techniques and OECD Health Data (2005) and he 
showed that pharmaceutical expenditure has a positive, but different effect on 
life expectancy for females and males of various ages. Finally, Guindon and 
Contoyannis (2012) examined the robustness of the findings of Cremieux et al., 
(2005) by considering the appropriateness of the data and statistical approach 
PHARMACEUTICAL EXPENDITURE AS A DETERMINANT OF HEALTH OUTCOMES… 
Estudios de Economía Aplicada, 2013: 379-396   Vol. 31-2 
383 
used. They found that the results obtained by Cremieux et al., are not robust to 
alternative specifications. 
On the other hand, there are some studies which refer to the Spanish case. 
García-Sempere and Peiró (2001) tried to identify the explicative factors that 
are associated with pharmaceutical spending. They used data about expenditure 
and socio-demographic characteristics in order to explain how these factors 
affect different health areas in the Valencian Community. They carried out the 
research doing multiple regression with information about 1997. Their results 
suggested that the percentage of the population over 67 years old, the mortality, 
the proportion of the population without studies or who only had primary 
studies are positively correlated with pharmaceutical expenditure. Other authors 
such as Cebria et al., (2003) studied the influence of multiple factors related 
with personal and professional characteristics of family doctors in the 
pharmaceutical expenditure per capita in primary attention. They studied 220 
doctors from Barcelona and they found that pharmaceutical spending increased 
with the doctor´s age, their experience, if the person has an indefinite work 
contract, if they work in various centers or if they feel emotionally tired. 
Finally, Cantarero and Pascual (2008) analyzed the impact of decentralization 
on health care outcomes in Spain using panel data over the period 1992 to 2003. 
They found that infant mortality is negatively related to income per capita, 
health care decentralization and the relative number of practitioners. 
Other authors have focused their research on pharmaceutical expenditure. 
For example, Aaaserud et al., (2006) made a review to determine the effects of 
pharmaceutical pricing and purchasing policies on drug use, healthcare utilisa-
tion, health outcomes and costs (expenditures). They included 10 studies of 
reference pricing and one study of index pricing. Most of the reference pricing 
studies were for senior citizens in British Columbia, Canada and they found 
relatively few studies of pricing policies. The majority of the studies dealt with 
reference pricing. They concluded that based on the evidence in their review, 
mostly from senior citizens in British Columbia, Canada, reference drug pricing 
can reduce third party drug expenditures by inducing a shift in drug use towards 
less expensive drugs. From another point of view, Navarro and Hernández 
(2006) analyzed the inclusion of uncertainty in Spanish economic evaluations 
published to establish the state of the art in this field. They concluded that, 
despite the fact that all published pharmaco-economic guidelines suggest the 
use of sensitivity analysis, only 64.61% of studies between 1995 and 2002 in 
Spain did so. 
Recently, Moreno-Torres et al., (2011) studied the impact of some measures 
taken in Spain to reduce costs; specifically pharmaceutical expenditure per 
capita, prescription per capita and the average price of pharmaceuticals financed 
by the public sector. They focused their study on Catalonia from 1995 to 2006 
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and an autoregressive integrated moving average (ARIMA) time series model 
was implemented, using dummy variables representing that measures. Their 
results showed that twelve of the sixteen measures were not effective in 
reducing the expenditure per capita, the average price of prescriptions or the 
number of prescriptions per patient, at least in the short term. 
Vogler et al., (2011) studied which pharmaceutical policies were imple-
mented in the European Countries consequences of the financial crisis. They 
used a sample of 33 European Countries which had been asked about pharma-
ceutical pricing and reimbursement in 2010. They analyzed the response rate 
and carried out a monitoring exercise, concluding that nearly ninety policy 
measures were identified in twenty-three of the thirty-three countries. 
Additionally the most common policy measures were about price reductions, 
changes in co-payments, VAT changes in medicines and changes in distribution 
margins. Finally, Toumi et al., (2012) carried out the project to build a model to 
assess the overall net effect of the entrance of new patented medicinal products 
versus those that are going off-patent, with a forecast horizon until 2016, on 
seven selected European Union Member States’ pharmaceutical budgets: 
France, the United Kingdom, Germany, Poland, Portugal, Greece and Hungary. 
They concluded that in light of the pharmaceutical policy analysis for each 
country, far-reaching changes were seen in the drug market access environment 
in most of the Members States under the study. Pricing and reimbursement 
regulations have shown substantial strengthening trends. Moreover, it was 
found that there is a wide variability between countries concerning generic entry 
policy such as time to market entry (from 0 day for the United Kingdom and 
Germany, to 270 days for Greece), penetration rate (from 25% for Greece and 
Portugal, to 100% for Hungary) and price reduction versus the branded product 
(from 45% for Poland, to 75% for the United Kingdom). Even if Europe ap-
pears as a leader for the biosimilar market, accounting for 80% of global 
spending on these molecules, little information was available about biosimilar 
pricing and reimbursement policies. 
In summary, there are many empirical studies which analyze the relationship 
between pharmaceutical expenditure and health outcomes, but there is no con-
sensus about the significance of that correlation. 
3. DATA AND METHODOLOGY 
3.1. Data 
The data used in the analysis have been obtained from the OECD Health 
Data (2012). This dataset contains aggregated data for the OECD country mem-
bers. It covers wide homogenized information about health, such as health care 
resources, health care expenditure or health status, among others. Besides, it 
contains information about population and socio-economic characteristics, such 
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as the as level of education or employment. Finally, it also has information 
about macroeconomic references such as the Gross Domestic Product (GDP). 
This allows us to compare the results for the different countries in the OECD. 
We have focused our study in nine European Union (EU) countries, Denmark, 
Finland, France, Germany, Ireland, Italy, Portugal, Spain and Sweden, from 
1995 to 20101. As our dependent variables, we have chosen life expectancy at 
birth in years by gender and infant mortality (deaths per 1000 live births). Fur-
thermore, we have used available information about GDP and pharmaceutical 
and other medical non-durables expenditure, both of them in per capita Pur-
chasing Power Parity (US$ PPP) terms. On the other hand, we have considered 
two variables about the consumption of fruit and vegetables (kilos per capita) 
and alcohol (liters per capita). Finally, we have included a variable that indi-
cates the percentage of population which is civilian employees. In Table 1, we 
can see the definitions and descriptive statistics of the variables. 
Table 1 
Variables, definitions and descriptive statistics 
Variable Definition Mean SD Min Max 
LE_MALE Life expectancy at birth - Male 75.89 1.82 71.60 79.50 
LE_FEMALE Life expectancy at birth - Female 81.87 1.64 77.90 85.30 
INFANTMORT Infant mortality 4.15 1.01 2.30 7.40 
GDP Gross domestic product per capita 27935.94 6789.44 13498.50 45532.00 
PHARMA_OTHER_EXP Pharmaceutical and other medical non-durables per capita 392.03 128.61 135.79 686.37 
ALCOHOL Liters per capita of alcohol consumption 11.01 2.43 5.80 15.10 
GOOD_FOOD Kilos of fruit and vegetables per capita 218.21 56.98 117.50 350.20 
TECP Percentage of population who are civilian employees 43.79 4.52 31.60 51.00 
ANTIBACTERIALS Daily dosage per 1000 inhabitants and  per day 19.89 5.95 12        34.1 
Source: Authors’ elaboration based on OECD Health data. 
Our data established that life expectancy at birth is lower for men than 
women, being 75.89 years for men and 81.87 years for women for the entire 
selected sample. Infant mortality has a rate of 4.15. The GDP, as mean of the 
sample is 27935.94$ per capita (PPP) while pharmaceutical and other spending 
amount to 393$ pc on average. Finally, the consumption of fruit and vegetables 
as an indicator of a good diet is on average, 218.21 kilos but there are a lot of 
                                               
1 The most important problem is the availability of homogeneous data because if we extend the 
period we would have a huge loss of information, especially in the variable “pharmaceutical ex-
penditure and others”. 
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differences between the minimum (117.50 kilos) and the maximum (350.20 
kilos).There are also significant differences in alcohol consumption between the 
data sample (from 5.80 liters per capita to 15.10 liters). 
3.1.1. Descriptive analysis 
In order to have a better knowledge of the situation we are going to study 
how the chosen indicators have been changing across countries and time. It is 
necessary to remember that advances in science and technology are allowing 
people to live longer and are also reducing infant mortality rates. The main 
consequence is the ageing of the population and the consequent change in the 
demographic structure, which is one of the main causes of increase in public 
spending on health and social services, in the same way it means an increase in 
pharmaceutical consumption of people who live longer but have lots of diseases 
and chronic illnesses. That means that unless the ageing of the population and 
the growth of life expectancy are indicators of the success of welfare European 
societies, they have not been in parallel with the reduction of  the number of 
diseases suffered (Rodriguez-Cabrero, 2007). The OECD (2012), in the second 
edition of Health at a Glance, presented comparable data for selected indicators 
of health and health systems in 35 European countries up to 2010. That publica-
tion provides detailed information on health expenditure and its trends, using 
results from the OECD, Eurostat and WHO annual joint health accounts ques-
tionnaire. In recent years, some of the results are that European countries have 
achieved benefits in health; the improvement in life expectancy can be ex-
plained by the improvement of living conditions, but also for better access to 
care and the quality of that care.  
It can be appreciated in Figure 1 that the most significant evolution in phar-
maceutical spending is referent to Ireland (5) which changed from 135.79 in 
1995 to 686.37 $ in 2010, being the country with higher spending in the last 
year. Denmark (1), on the contrary, is the country with the least growth from 
169.50 in 1995 to 330.95 $ in 2010 and also the country with lower expenditure 
in 2010. 
Life expectancy at birth is on average for all countries and all years set at 
78.89 years, Spain and Italy are the countries where population has a higher life 
expectancy at birth, contrary to Portugal which has on average the lowest. That 
information relates to the infant mortality rate, which presents the highest indi-
cator in Portugal; on the other hand, on average, Finland has the lowest rate. 
(See Figure 2). 
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Figure 1 
Evolution of pharmaceutical spending per countries 
 
Notes: The abscissa represents the time period. 
Source: Authors’ elaboration based on OECD Health data. 
Figure 2 
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Figure 2 (continue) 










Source: Authors’ elaboration based on OECD Health data. 
The relationship between the pharmaceutical variable and the two selected 
outcomes is expected to be in contrary ways. We would expect pharmaceutical 
spending to be associated with high life expectancy and also with low infant 
mortality rate. If our premise is not true, countries which spend more will not 
have the best results, so there could be some inefficiencies to study and eva-
luate.  
3.2. Method 
The literature on health economics has suggested different socio-economic 
determinants on health outcomes. However, the choice of the explanatory varia-
bles is often restricted by the availability and quality of the data. Therefore, our 
empirical model to estimate is the classic one for this kind of studies proposed 
in the literature review and adapted for the European case. 
Specifically in this paper we are working with time-series cross-section data, 
specifically we have an unbalance panel of 9 UE-countries over the period 












__   
Then, the proposed model tries to contrast the relationship between health 
outcomes (Life expectancy at birth for females and males, and Infant mortality) 
and the expenditures in pharmacy and other medical non-durables, with 
different explanatory variables for the European case. 
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In order to explore the robustness of the empirical results, the analysis is di-
vided into two sections: section one examines the relationship between our bat-
tery of independent variables and health outcomes using a fixed/random effects 
model due to the results reported by the Hausman test (1978). We applied one-
way and two-way2 fixed/random effects models. On the other hand, in the 
second step we re-estimate the model with panel-corrected standard errors 
(PCSE), which assumes that the disturbances are by default heteroskedastic and 
contemporaneously correlated across panels. Once again, we check the robust-
ness of the results allowing temporal and country effects.  
4. RESULTS 
The estimation results are presented synthetically summarized in Tables 2-4. 
Thus, in the first two tables the determinants of life expectancy for females and 
males are analyzed respectively, while the last one shows the results concerning 
infant mortality. 
Table 2 
Panel data results. Dependent Variable: Life expectancy - Females 
Variables FE/RE PCSE 
LN_PIB 3.640 0.440 1.127 0.093 4.387 0.481 
Std error 0.579 0.913 0.526 0.585 0.709 1.237 
P-value 0.000 0.630 0.032 0.874 0.000 0.698 
LN_PHARMA_OTHER 1.342 1.987 3.099 2.576 0.749 1.377 
Std error 0.387 0.373 0.430 0.437 0.434 0.477 
P-value 0.001 0.000 0.000 0.000 0.085 0.004 
ALCOHOL -0.173 -0.131 -0.162 -0.158 -0.164 -0.102 
Std error 0.034 0.033 0.030 0.030 0.039 0.035 
P-value 0.000 0.000 0.000 0.000 0.000 0.004 
GOOD_FOOD 0.002 0.002 0.001 0.000 0.002 0.002 
Std error 0.001 0.001 0.002 0.002 0.001 0.001 
P-value 0.213 0.081 0.695 0.800 0.193 0.062 
TCEP -0.095 -0.040 -0.108 -0.121 -0.088 -0.015 
Std error 0.019 0.021 0.018 0.019 0.020 0.025 
P-value 0.000 0.064 0.000 0.000 0.000 0.564 
Hausman statistic and prob (Hausman) 0.350 0.711     
Temporal effects NO YES NO YES NO NO 
Country effects NO NO NO NO YES NO 
Temp. and country effects NO NO NO NO NO YES 
Source: Authors’ elaboration. 
                                               
2 Not including year dummies could be problematic because there are time trends and year spe-
cific shocks. 
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As we can see, coefficients are statistically significant and in most cases 
have the expected signs according to the priori economic criteria. Additionally, 
it could be said that the estimates are robust and consistent with the inclusion of 
different specifications. Thereby, it is noticed that after applying the Hausman 
test (1978) we always use random effects; the only exception is when we intro-
duce time effects for the infant mortality dependent variable. 
As expected, income and expenditures in pharmacy and other medical non-
durables have a clear positive effect on a health indicator (life expectancy at 
birth), while its influence is negative for the other (infant mortality), in all cases 
the magnitude for the variables is higher for men than for women. 
Regarding the variables related with habits and lifestyles: alcohol and "good 
food", both are also significant with the opposite sign as the variable in question 
and the dependent variable in each case. Only its effect is a bit confusing for 
infant mortality, so it may be taken with caution. Besides, the relative variable 
of civilian employees shows a negative effect on life expectancy for both fe-
males and males.  
Table 3 
Panel data results. Dependent Variable: Life expectancy - Males 
Variables FE/RE PCSE 
LN_PIB 5.099 0.310 4.092 3.329 5.426 -0.632 
Std error 0.563 0.988 0.421 0.510 0.545 0.992 
P-value 0.000 0.753 0.000 0.000 0.000 0.524 
LN_PHARMA_OTHER 1.769 2.460 1.698 1.318 1.501 2.315 
Std error 0.376 0.380 0.319 0.321 0.366 0.437 
P-value 0.000 0.000 0.000 0.000 0.000 0.000 
ALCOHOL -0.265 -0.171 -0.258 -0.256 -0.237 -0.128 
Std error 0.033 0.033 0.019 0.019 0.046 0.036 
P-value 0.000 0.000 0.000 0.000 0.000 0.000 
GOOD_FOOD 0.001 0.000 0.003 0.002 0.001 0.000 
Std error 0.001 0.001 0.001 0.001 0.002 0.001 
P-value 0.561 0.899 0.007 0.036 0.667 0.949 
TCEP -0.138 -0.062 -0.067 -0.078 -0.137 -0.035 
Std error 0.018 0.022 0.013 0.012 0.019 0.023 
P-value 0.000 0.005 0.000 0.000 0.000 0.120 
Hausman statistic and prob (Hausman) 0.899 0.585     
Temporal effects NO YES NO YES NO NO 
Country effects NO NO NO NO YES NO 
Temp. and country effects NO NO NO NO NO YES 
Source: Authors’ elaboration.   
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Table 4 
Panel data results. Dependent Variable: Infant mortality 
Variables FE/RE PCSE 
LN_PIB -1.425 0.804 -1.473 -0.339 -0.995 0.629 
Std error 0.501 1.335 0.453 0.518 0.725 1.206 
P-value 0.004 0.548 0.001 0.512 0.170 0.602 
LN_PHARMA_OTHER -1.475 -2.084 -1.256 -0.818 -1.703 -1.960 
Std error 0.378 0.676 0.322 0.356 0.520 0.588 
P-value 0.000 0.003 0.000 0.022 0.001 0.001 
ALCOHOL 0.238 0.255 0.180 0.180 0.265 0.223 
Std error 0.036 0.056 0.029 0.024 0.052 0.055 
P-value 0.000 0.000 0.000 0.000 0.000 0.000 
GOOD_FOOD 0.001 0.000 0.002 0.004 -0.001 -0.001 
Std error 0.002 0.002 0.002 0.002 0.002 0.002 
P-value 0.374 0.876 0.176 0.013 0.709 0.688 
Hausman statistic and prob (Hausman) 0.240 0.002     
Temporal effects NO YES NO YES NO NO 
Country effects NO NO NO NO YES NO 
Temp. and country effects NO NO NO NO NO YES 
Source: Authors’ elaboration. 
Moreover, to show the robustness of the results, we have focused on life ex-
pectancy as health outcome. We have made a second analysis using the same 
methodology, that is PCSE, but we have changed our referent independent 
variable. Instead of using pharmaceutical and other medical non-durable ex-
penditures, we have used antibacterial consumption for systemic use (which is 
measured by daily dosage per 1000 inhabitants-day), as proxy variable of phar-
maceutical consumption, taking into account that if there is an increase in 
pharmaceutical consumption, then there would be an increase on pharmaceuti-
cal expenditure. The over-use of antibiotics is the main force driving the in-
crease of bacterial resistance, representing a major threat to public health 
(Filippini et al., 2012). 
Table 5 
Panel data results. Dependent Variable: Life expectancy by sex 
Variables Female Male 
LN_PIB 4.610 0.271 5.486 4.018 5.914 2.995 7.444 4.134 
Std error 0.836 0.864 0.439 1.151 0.542 0.816 0.419 1.333 
P-value 0.000 0.754 0.000 0.000 0.000 0.000 0.000 0.002 
Antibacterials 0.021 0.040 0.018 0.024 0.010 0.003 0.009 0.039 
Std error 0.031 0.018 0.017 0.013 0.020 0.016 0.021 0.021 
P-value 0.508 0.024 0.306 0.066 0.612 0.831 0.688 0.067 
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Table 5 (continue) 
Panel data results. Dependent Variable: Life expectancy by sex 
Variables Female Male 
ALCOHOL -0.137 -0.143 -0.155 -0.123 -0.226 -0.226 -0.209 -0.167 
Std error 0.056 0.044 0.046 0.041 0.039 0.032 0.059 0.054 
P-value 0.014 0.001 0.001 0.003 0.000 0.000 0.000 0.002 
GOOD_FOOD 0.004 0.002 0.002 0.003 0.005 0.002 0.002 0.000 
Std error 0.002 0.002 0.002 0.001 0.002 0.002 0.002 0.002 
P-value 0.046 0.293 0.220 0.036 0.004 0.168 0.315 0.878 
TCEP -0.143 -0.147 -0.108 -0.059 -0.101 -0.104 -0.150 -0.076 
Std error 0.050 0.035 0.025 0.030 0.034 0.028 0.029 0.035 
P-value 0.004 0.000 0.000 0.053 0.003 0.000 0.000 0.028 
Temporal effects NO YES NO NO NO YES NO NO 
Country effects NO NO YES NO NO NO YES NO 
Temp. and country effects NO NO NO YES NO NO NO YES 
Source: Authors’ elaboration. 
Coefficients have the same signs as in previous analysis. This is, income and 
drug consumption have a positive effect on life expectancy at birth. But bad life 
styles affect in a negative way. We can see these results in Table 5. 
In short, as is expected, income is the most important factor to explain health 
outcomes. 
5. CONCLUSIONS 
There are many studies which study the relationship between public ex-
penditure on health and positive health outcomes. In our analysis, we have fo-
cused on the relationship between pharmaceutical expenditure and several 
health outcomes. In particular, we have analyzed life expectancy at birth (by 
gender) and infant mortality as health outcomes. To carry this out, we have used 
the OECD Health Data (2012) and we have applied panel data techniques. To 
prove the consistency of the results, we have used different approaches 
considering temporal and country effects. In our results, the coefficients are 
statistically significant and in most cases have the expected signs according to 
the priori economic criteria. The estimates are robust and consistent with the 
inclusion of different specifications. As expected, income and pharmaceutical 
and other medical non-durables expenditures have a clear positive effect on life 
expectancy at birth, while its influence is negative for infant mortality. 
The results indicate that expenditure on health, and particularly, pharmaceu-
tical expenditure and drug consumption, produce better health outcomes, so it 
should be taken into account by policy makers. Furthermore, we have found that 
alcohol and fruit and vegetable consumption have the expected effect on health 
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outcomes, so it would be interesting, from the policy makers’ point of view, to 
implement policies that encourage healthy lifestyles. 
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